Trial reportMenopause (New York, N.Y.)2016
Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition.
Trial report in Menopause (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03526523 (Testing the Efficacy of Mindfulness-based Stress Reduction as a Prophylactic Intervention in the Prevention of Perimenopausal Depression), which is not on this map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Testing the Efficacy of Mindfulness-based Stress Reduction as a Prophylactic Intervention in the Prevention of Perimenopausal Depression: a Randomized Trial
Who cites it
58 citing papers in PubMed, 134 citations in OpenAlex.
- Hormone sensitivity predicts the beneficial effects of transdermal estradiol on reward-seeking behaviors in perimenopausal women: A randomized controlled trial.Psychoneuroendocrinology · 2023Trial
- Baseline anxiety-sensitivity to estradiol fluctuations predicts anxiety symptom response to transdermal estradiol treatment in perimenopausal women - A randomized clinical trial.Psychoneuroendocrinology · 2022Trial
- The short-term effects of estradiol, raloxifene, and a phytoestrogen in women with perimenopausal depression.Menopause (New York, N.Y.) · 2021Trial
- Progesterone modulates theta oscillations in the frontal-parietal network.Psychophysiology · 2020Trial
- Transdermal estradiol for postpartum depression: results from a pilot randomized, double-blind, placebo-controlled study.Archives of women's mental health · 2020Trial
- Effects of perimenopausal transdermal estradiol on self-reported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms.Menopause (New York, N.Y.) · 2019Trial
- Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.JAMA psychiatry · 2018Trial
- Ovariectomy, but not moderate intermittent hypoxia, promotes respiratory instability and risk of obesity in adult female rats.Experimental physiology · 2026Article
- Beyond Menopausal Stage: Symptom Burden, Self-Efficacy, and Psychological Distress.Journal of clinical medicine · 2026Article
- Synaptic Actions of Estradiol in the Brain's Reward System: Linking Mechanisms to Behavior and Disease.Biological psychiatry global open science · 2026Review
- Benzodiazepines for anxiety and depression: an updated overview of current use and major outcomes.Molecular biology reports · 2026Review
- The Impact of Estradiol Dynamics During the Menopause Transition on Depression Risk: A Narrative Review of Estradiol's Neurobiological Mechanisms.Biological psychiatry · 2026Review
- Affective Sensitivity to Ovarian Steroid Hormone Flux Across the Menstrual Cycle: Manifestations and Biopsychosocial Risk Factors.Annual review of clinical psychology · 2026Review
- Obsessive-compulsive disorder and menopause: a scoping review.Menopause (New York, N.Y.) · 2026Article
- Article
- The trajectory of depressive symptoms and the association with quality of life and suicidal ideation in patients with major depressive disorder.BMC psychiatry · 2025Article
- Chronic 17β-estradiol treatment improves negative valence, anhedonic profile, and social interactions in ovariectomized, middle-aged female rats.Frontiers in behavioral neuroscience · 2025Article
- Sex Differences in the Neurobiology of Fear and Anxiety.Current topics in behavioral neurosciences · 2025Review
- Antidepressant- and Anxiolytic-like Effects of Pomegranate: Is It Acting by Common or Well-Known Mechanisms of Action?Plants (Basel, Switzerland) · 2024Review
- VARIANCE AS A PREDICTOR OF HEALTH OUTCOMES: SUBJECT-LEVEL TRAJECTORIES AND VARIABILITY OF SEX HORMONES TO PREDICT BODY FAT CHANGES IN PERI- AND POSTMENOPAUSAL WOMEN.The annals of applied statistics · 2024Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe aim of the study was to examine the role of estradiol fluctuation in triggering depressive symptoms in the menopausal transition and assess the role of recent very stressful life events (VSLEs) as a moderating factor in this relationship.
methodsA total of 52 euthymic women in the menopausal transition or early postmenopause (age 45-60) who were assigned to the placebo arm of a randomized controlled trial of hormone therapy provided the data for this report. At enrollment, women's experience of recent VSLEs, depressive symptoms, serum estradiol, and progesterone were assessed. At months 1, 8, and 14, depressive symptoms and hormones were reassessed, and participants underwent a stressor battery involving a speech and a mental arithmetic task. Participants rated their feelings of anxiety, fear, anger, and rejection. The standard deviation of estradiol provided an index of hormone variability over the entire 14 months.
resultsGreater estradiol variability across the 14 months predicted greater depressive symptoms at month 14, though only in women reporting a higher number of VSLEs at baseline (39% of women reported ≤1 recent event). Greater estradiol variability also predicted greater feelings of rejection to the laboratory stressor at months 8 and 14. Furthermore, among women reporting higher VSLEs at baseline, feelings of rejection in response to the laboratory stressor at month 8 predicted depressive symptoms at month 14.
conclusionsThese data suggest that estradiol variability may enhance emotional sensitivity to psychosocial stress, particularly sensitivity to social rejection. Combined with VSLEs proximate to the menopausal transition, this increased sensitivity may contribute to the development of depressed mood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.